Developing new chemical reactions using transition metals for better medicines
Discovery and Development of Organic Reactions Catalyzed by Transition Metals Valuable for Medicinal Chemistry
This study is looking at new ways to use special metals to help create important compounds that can lead to better medicines, which could help patients get more effective treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-11014046 on NIH RePORTER |
What this research studies
This research focuses on creating and understanding new chemical reactions that use transition metals as catalysts to synthesize organic compounds essential for human health. By exploring how these catalysts work, the research aims to improve the efficiency and selectivity of chemical reactions, particularly those that modify complex molecules relevant to drug discovery. Patients may benefit from advancements in drug development that arise from these innovative synthetic methods, potentially leading to more effective medications.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals with conditions that require innovative drug therapies or those involved in clinical trials for new medications.
Not a fit: Patients who are not seeking new treatment options or those with conditions that are not addressed by the types of drugs being developed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective medications for various health conditions.
How similar studies have performed: Other research has shown success in using transition metal catalysts for drug development, indicating that this approach has the potential for significant advancements.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Hartwig, John F — University of California Berkeley
- Study coordinator: Hartwig, John F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.